
HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.